On March 18, the U.S. Food and Drug Administration approved a combination of the immunotherapy atezolizumab (Tecentriq) along with standard chemotherapy (carboplatin and etoposide) for patients who are starting treatment for extensive stage small cell lung cancer. This is the first immunotherapy approved up front, as a first treatment, for small cell lung cancer (SCLC). The approval was based on the IMPower133 clinical trial which showed that more patients survived longer when taking the combination than standard chemotherapy. Click here [...]
Small cell lung cancer (SCLC) makes up about 15% of lung cancer cases (the other 85% is non-small cell lung cancer) with around 30,000 Americans being diagnosed each year. 98% of SCLC cases are smoking-related (majority of those diagnosed being former smokers). With smoking rates decreasing in the past several decades, so have rates of SCLC. The current standard of care for patients diagnosed with SCLC is chemotherapy and radiation (surgery can be an option if diagnosed at an early [...]
WEBINAR: New Directions in Small Cell Lung Cancer Thursday, November 1, 2018 from 12:00PM- 1:00PM Do you or a loved one have small cell lung cancer and are looking for information on the latest treatments and advancements? Join us for a webinar on November 1 at 12:00PM EST to learn from experts in the field, hear personal survivor experiences and get your questions answered. Sign up today!
This week, the LCA team attended the 19th Annual World Conference on Lung Cancer (September 23-26, 2018) in Toronto, Canada. Jennifer C. King, PhD, Director of Science and Research, gives us the scoop on some of the research and treatment breakthroughs, and how they impact you! https://youtu.be/Q2S7akrHUVQ SCREENING REDUCES MORTALITY! Results from the Dutch-Belgium Lung Cancer Screening trial (NELSON) showed that lung cancer screening significantly reduces lung cancer mortality. In this trial, which was more favorable than the National Lung [...]
By: Jennifer C. King, PhD, Director of Science and Research, Lung Cancer Alliance Last week, the United States Food and Drug Administration (FDA) approved Opdivo (nivolumab) as a new treatment for small cell lung cancer. This is the first new drug for small cell lung cancer that has been approved in decades. The lung cancer community should be very excited about this advance and the future of small cell research. Opdivo is a type of immunotherapy called a checkpoint inhibitor. [...]
Friday, August 17, 2018 – Today the U.S. Food and Drug Administration approved Opdivo (nivolumab), an immunotherapy treatment, for patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy. Accelerated approval was granted for this therapy due to positive results of a recent study, Phase 1/2 CheckMate -032 trial. This is not only the first immunotherapy treatment approved for SCLC, but also the first new treatment for SCLC in [...]
By Jennifer C. King, PhD, Director of Science & Research at Lung Cancer Alliance Research on the treatment of lung cancer has been moving quickly and 2017 was no different. Precision medicine was a key theme this year - there have been many treatment advances that depend on the gene changes in each person’s lung cancer. Approvals of New Drugs and Molecular Tests The United States Food and Drug Administration (FDA) has approved brand new drugs for non-small cell lung [...]